19 IDENTIFICATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT HIGH RISK OF URGENT CARE UTILIZATION THROUGH IBD QORUS, A LEARNING HEALTHCARE SYSTEM

2019 ◽  
Vol 156 (3) ◽  
pp. S2
Author(s):  
Jason K. Hou ◽  
Anthony Xu ◽  
Brant Oliver ◽  
Siddharth Singh ◽  
Julie Weatherly ◽  
...  
2020 ◽  
Vol 26 (Supplement_1) ◽  
pp. S54-S55
Author(s):  
Gil Melmed ◽  
Brant Oliver ◽  
Jason Hou ◽  
Donald Lum ◽  
Donna Gerner ◽  
...  

Abstract Introduction There is significant variation in processes and outcomes of care for patients with inflammatory bowel disease (IBD), suggesting opportunities to improve quality of care. Recent efforts to define quality measures for IBD have identified emergency room (ER) visits, hospitalizations, corticosteroid use, and opioid use as indicators of care quality. We hypothesized that IBD care could be improved through a structured quality improvement (QI) program. Methods We utilized the Breakthrough Series Collaborative approach developed by the Institute for Healthcare Improvement to improve care for adults with IBD. We identified primary and secondary drivers of urgent care need for patients including those at high risk for ER use, and a multi-stakeholder panel developed 19 practice change ideas that could influence those drivers. Between January 2018 and May 2019, clinical sites participating in a QI collaborative across the United States tested and implemented various change ideas, shared ongoing results during coached monthly webinars, and participated in 3 in-person meetings to learn QI methods and share best practices. Patient-reported outcomes (PROs) were collected at clinical visits, including recent ER use and hospitalizations, use of steroids and narcotics, and measures of care utilization. Providers rated whether patients were at high risk for urgent care needs. Site performance on key measures were monitored using statistical control charts, with assessment for common cause (due to chance) variation and special cause (non-random) variation. Results We collected data prospectively from 20,382 discrete visits at twenty-six participating clinical practices (14 academic/university, 12 private/community). Disease type included Crohn’s disease (58%), ulcerative colitis (39%), and other (3%); 54% were female. During the 15-month project period, improvement with special cause variation was noted across multiple measures. Collaborative-wide decreases were seen in ER utilization (18% to 14%, relative reduction of 22%; Figure), hospitalization (14% to 11%, relative reduction of 21%), steroid use (14% to 10%, relative reduction of 29%), and narcotic utilization (8% to 4%, relative reduction of 50%). Successful change ideas tested by sites included proactive maintenance of a “high risk” patient list, reserved outpatient visits for urgent needs, “morning-after” contact with patients who went to the ER, patient education about how and when to get help, and proactively scheduling earlier follow-up for high risk patients. Conclusions Outcomes of IBD care were improved using a structured QI program that facilitates small changes in practice structure, sharing of best practices across sites, and ongoing feedback. Spread of successful change ideas may facilitate broad improvement in IBD care and significant cost savings when applied to a large population. Changes in Key Measures Over Time Statistical Process Control Chart Showing Monthly Proportion of Patients Reporting Recent ER Utilization


2020 ◽  
Vol 158 (3) ◽  
pp. S110-S111
Author(s):  
Jeffrey Berinstein ◽  
Shirley Cohen-Mekelburg ◽  
Calen Steiner ◽  
Megan Mcleod ◽  
Mohamed Noureldin ◽  
...  

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 197-199
Author(s):  
M Patterson ◽  
M Gozdzik ◽  
J Peña-Sánchez ◽  
S Fowler

Abstract Background Appropriate management of inflammatory bowel disease (IBD) often requires multiple specialist appointments per year. Living in rural locations may pose a barrier to regular specialist care. Saskatchewan (SK) has a large rural population. Prior to COVID-19, telehealth (TH) in SK was not routinely used for either patient assessment or follow up. Furthermore, TH was exclusively between hospitals and specific TH sites without direct contact using patient’s personal phones. Aims The objective of this study was to assess the differences in demographics, disease characteristics, outcomes, and health care utilization between patients from rural SK with IBD who used TH and those who did not. Methods A retrospective chart review was completed on all rural patients (postal code S0*) with IBD in SK who were followed at the Multidisciplinary IBD Clinic in Saskatoon between January 2018 and February 2020. Patients were classified as using TH if they had ever used it. Information on demographics, disease characteristics, and access to IBD-related health care in the year prior to their last IBD clinic visit or endoscopy was collected. Data was not collected for clinic visits after March 1, 2020 as all outpatient care became remote secondary to the COVID-19 pandemic. Mean, standard deviations, median and interquartile ranges (IQR) were reported. Mann-Witney U and Chi-Square tests were used to determine differences between the groups. Results In total, 288 rural SK IBD patients were included, 30 (10.4%) used TH and 258 (89.6%) did not. Patient demographics were not significantly different between the two groups; although, there was a statistically significant difference in the proportion of ulcerative colitis patients (17% TH vs. 38% non-TH, p=0.02). The percentage of patients with clinical remission was 87% for TH patients and 74% for non-TH patients (p=0.13). There were no significant differences in health care utilization patterns and biochemical markers of disease, including c-reactive protein (CRP) and fecal calprotectin (FCP) (p>0.05). Conclusions Prior to the pandemic, a small percentage of patients with IBD in rural SK ever used TH. A small proportion of UC patients used TH. No significant differences in disease characteristics, outcomes, or health care utilization were identified. Further study is warranted to identify barriers to use of this technology to tailor care to this patient group and improve access to care, especially now as the COVID-19 pandemic has drastically changed the use of virtual care. Funding Agencies None


2017 ◽  
Vol 35 (1-2) ◽  
pp. 50-55 ◽  
Author(s):  
Jacques Cosnes

Background: Treatment of inflammatory bowel disease (IBD) in patients with prior malignancy is challenging because therapeutic immunosuppression required for controlling IBD activity may increase the risk of cancer recurrence. Key Messages: Contrary to the observations in the post-transplant population, retrospective observational studies of IBD patients with prior malignancy have not demonstrated that immunosuppressive drugs increased significantly the risk of new or recurrent cancer. However, these studies are highly biased and do not permit the use of these drugs. Factors like the time since treatment completion, severity, and subtype of prior cancer should be weighed along with the current IBD activity before choosing the best therapeutic strategy. In practice, most cases of prior cancer require a delay of at least 2 years before starting or resuming immunosuppressants, including anti-TNF agents. This delay should be extended to 5 years in cancer with a high risk of recurrence including cancer of the urinary tract, gastrointestinal cancer, leukemias, and multiple myeloma. A special attention should be paid to cancers with a high risk of late metastasis (breast, melanoma, renal cell carcinoma). Enteral nutrition, Budesonide, mesalamine, and limited intestinal resection should be considered following the completion of cancer treatment and prior to the safe initiation of immunosuppressive treatment for IBD. Thiopurines should be avoided in case of prior Epstein-Barr virus-related lymphoma, HPV-related carcinomas, and cancer of the urinary tract. Methotrexate and anti-TNF agents seem to be safe except for the risk of recurrent melanoma for the latter. Conclusion: IBD patients with prior malignancy should benefit from individual decisions made on a case-by-case basis.


Author(s):  
Daniel Azuara ◽  
Susanna Aussó ◽  
Francisco Rodriguez-Moranta ◽  
Jordi Guardiola ◽  
Xavier Sanjuan ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Gil Y. Melmed ◽  
Brant Oliver ◽  
Jason K. Hou ◽  
Donald Lum ◽  
Siddharth Singh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document